CX Institutional Buys 2,185 Shares of HCA Healthcare, Inc. (NYSE:HCA)

CX Institutional lifted its position in HCA Healthcare, Inc. (NYSE:HCA) by 16.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,707 shares of the company’s stock after purchasing an additional 2,185 shares during the period. CX Institutional’s holdings in HCA Healthcare were worth $4,715,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HCA. Legacy Investment Solutions LLC acquired a new position in HCA Healthcare during the third quarter worth $39,000. Capital Performance Advisors LLP purchased a new stake in HCA Healthcare in the 3rd quarter worth approximately $41,000. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of HCA Healthcare during the second quarter worth $33,000. Canoe Financial LP purchased a new position in HCA Healthcare during the third quarter worth about $41,000. Finally, Northwest Investment Counselors LLC acquired a new position in shares of HCA Healthcare during the 3rd quarter valued at about $44,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now directly owns 52,702 shares in the company, valued at $18,445,700. The trade was a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the sale, the insider now directly owns 6,843 shares of the company’s stock, valued at approximately $2,415,579. This represents a 29.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Trading Down 0.9 %

NYSE:HCA opened at $322.29 on Friday. HCA Healthcare, Inc. has a one year low of $279.93 and a one year high of $417.14. The firm has a market capitalization of $81.64 billion, a price-to-earnings ratio of 14.45, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64. The business has a fifty day moving average price of $314.50 and a 200-day moving average price of $352.84. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Friday, January 24th. The company reported $6.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same period last year, the firm posted $5.90 earnings per share. Sell-side analysts forecast that HCA Healthcare, Inc. will post 21.75 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Barclays lowered their price objective on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Truist Financial decreased their price objective on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Raymond James downgraded shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. StockNews.com lowered HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, TD Cowen dropped their price target on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $385.27.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.